Know Cancer

or
forgot password

A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Thrombocytopaenia

Thank you

Trial Information

A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin


Inclusion Criteria:

Inclusion Criteria Subjects eligible for enrolment in Phase I and II of
the study must meet all of the following criteria:

- Signed written informed consent.

- Age ≥ 18 years.

- Subjects with confirmed solid tumor and scheduled to receive at least two cycles of
either gemcitabine monotherapy OR gemcitabine in combination with carboplatin or
cisplatin at the same dosages and schedule in the study. Novel anticancer agents
(e.g. bevacizumab, erlotinib) may be allowed if considered the standard treatment by
the investigator.

- Note: For patients scheduled to receive any novel anticancer agents (e.g.
bevacizumab, erlotinib), consultation and approval from the GSK medical monitor
should occur before the subject is enrolled into the study.

- Life expectancy of at least 3 months, in the opinion of the investigator.

- ECOG-Zubrod performance status ≤ 2

- For Phase I: Pre-chemotherapy platelet count ≤ 300 Gi/L in the screening period
before the subject start their first planned cycle of treatment with gemcitabine
monotherapy OR gemcitabine in combination with carboplatin or cisplatin in the study.

- For Phase II (Part 1 and 2): Subjects must meet one of the following platelet count
entry criteria:

1. Platelet count < 150 Gi/L in the screening period as measured within 3 days
before Day 1of the first cycle in this disease setting, OR

2. Subjects started chemotherapy for this disease setting and had platelet count <
150 Gi/L on Day 1 in the preceding cycle before entry into the study, OR

3. Platelet count < 100 Gi/L at Day 8 in the preceding cycle before entry into the
study, OR

4. Platelet count < 100 Gi/L at Day 15 in the preceding cycle before entry into the
study (for subjects receiving Gemcitabine monotherapy) Note: For any of these
platelet counts, a repeated platelet count may be allowed only once to ensure
that the subject meets the above platelet count criteria and the latest count
will be taken for the assessment of eligibility to the study..

- Subjects with previous chemotherapy treatment in a previous disease setting are
allowed provided they have recovered from chemotherapy related toxicity except
alopecia (and the lab parameters mentioned in Inclusion criteria in #9).

- Adequate baseline organ function defined by the criteria below:

- SYSTEM LABORATORY VALUES

- Hematologic

- Platelets, see Inclusion criteria

- ANC (absolute neutrophil count) ≥1.5 × 109/L

- Hemoglobin ≥9 g/dL

- Prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT) Within 80
to 120% of the normal range

- Hepatic

- Albumin ≥2.5 g/dL

- Serum bilirubin ≤1.5 x ULN AST and ALT

- 3 × ULN without liver metastases

- 5 × ULN if documented liver metastases

- Renal

- Serum Creatinine ≤ 1.2 x ULN

- Subjects with AST, ALT or bilirubin values outside the range(s) in the table due to
Gilbert's syndrome or asymptomatic gall stones are not excluded.

- Women of childbearing potential must have a negative serum pregnancy test within 2
weeks prior to randomization and agree to use effective contraception, during the
study and for 4 weeks following the last dose of investigational product.

- Men with a female partner of childbearing potential must have either had a prior
vasectomy or agree to use effective contraception from 2 weeks prior to randomization
until 13 weeks after the last dose of study treatment.

- Able to swallow and retain orally administered medication and does not have any
clinically significant gastrointestinal abnormalities that may alter absorption such
as malabsorption syndrome or major resection of the stomach or bowels.

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

- Lactating females.

- Pre-existing cardiovascular disease (congestive heart failure, New York Heart
Association [NYHA] Grade III/IV), or arrhythmia known to increase the risk of
thromboembolic events (e.g. atrial fibrillation), unstable angina, or subjects with a
QTc >450 msec (QTc >480 msec for subjects with Bundle Branch Block) at study entry,
or myocardial infarction within the preceding 6 months. Subjects with a34 pacemaker
or defibrillator are not excluded provided that their cardiac function is within
normal ranges.

- Note: For patients with pre-existing NYHA Grade II cardiovascular disease, the
investigator should consult with GSK medical monitor before enrolling the subject
into the study.

- Patients with known factor V leiden, antiphospholipid antibody syndrome, prothrombin
gene mutations, ATIII deficiency, protein C deficiency, protein S deficiency OR
recent history of arterial or venous thrombosis (stroke, transient ischemic attack,
myocardial infarction, deep vein thrombosis or pulmonary embolism) within the
preceding 6 months.

- Note: for patients other with known risk factors for thromboembolism e.g., diabetes,
hypercholesterolemia, recent major surgery etc., the investigator should consult with
GSK medical monitor before enrolling the patient into the study and all risk factors
should be documented in the CRF.

- Prior surgery within two weeks before study randomization or radiotherapy (RT) within
four weeks before study randomization. Subjects with prior surgery or RT are not
permitted into the study unless they have completely recovered from surgery and/or
acute RT toxicity except for alopecia.

- Note: Note: patients with minor surgeries or outpatient procedures (e.g. insertion of
central venous catheter) are immediately allowed in the study provided that there
were no complications from the procedure or surgery.

- History of prior radiotherapy to more than 20% bone marrow bearing sites.

- History of platelet agglutination abnormality, platelet disorders or dysfunction or
bleeding disorder that prevents reliable measurement of platelet counts.

- Subjects with a history of CNS metastases or clinical signs or symptoms of brain
and/or leptomeningeal metastases confirmed by CT or MRI brain scan unless properly
treated. Subjects with CNS metastases treated by neurosurgical resection or brain
biopsy performed within 3 months prior to randomization will be excluded.

- Treated brain metastases are defined

- Having no evidence of progression or hemorrhage after treatment and no ongoing
requirement for dexamethasone, as ascertained by clinical examination and brain
imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are
allowed.

- Treatment for brain metastases may include whole brain radiotherapy (WBRT),
radiosurgery (RS; Gamma Knife, LINAC, or equivalent) or a combination as deemed
appropriate by the treating physician.

Note: if subject has performed a CT scan immediately prior to the screening period and CT
could not be repeated, an MRI should be performed in the screening period to exclude the
development of brain metastases and/or the progression of the pre-existing brain
metastatic lesion(s).

- Administration of an investigational drug within 30 days or 5 half-lives, whichever
is longer, preceding the first dose of investigational product in the study.
Concurrent participation in another interventional clinical trial or administration
of any investigational drug during the study is also not permitted.

- A known immediate or delayed hypersensitivity reaction or idiosyncrasy that, in the
opinion of the Investigator or GSK Medical Monitor is due to drugs chemically related
to eltrombopag or excipients (e.g. mannitol).

- Subjects with known Hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV).
Subjects with Gilbert's Syndrome are permitted into the study.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care

Outcome Measure:

Phase I: Primary Endpoint Safety and tolerability of eltrombopag as assessed by evaluating adverse events (AE) reporting, and changes from baseline in other safety parameters including clinical laboratory values

Outcome Time Frame:

nine months

Safety Issue:

No

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

GlaxoSmithKline

Authority:

Israel: Helsinki Committee, Tel Aviv Sourasky Medical Center

Study ID:

112765

NCT ID:

NCT01147809

Start Date:

June 2010

Completion Date:

May 2016

Related Keywords:

  • Thrombocytopaenia
  • Solid Tumor
  • Eltrombopag
  • chemotherapy-induced thrombocytopenia
  • Thrombocytopenia
  • Thrombocytopenia

Name

Location

GSK Investigational SitePhoenix, Arizona  85013 - 4496
GSK Investigational SiteLittle Rock, Arkansas  72205
GSK Investigational SiteBakersfield, California  93309
GSK Investigational SiteGainesville, Florida  32610
GSK Investigational SiteSt. Louis, Missouri  63141
GSK Investigational SiteFort Worth, Texas  76104
GSK Investigational SiteSavannah, Georgia  31405
GSK Investigational SitePittsburgh, Pennsylvania  15213
GSK Investigational SiteColumbia, South Carolina  29210
GSK Investigational SiteKansas City, Kansas  66160
GSK Investigational SiteOregon City, Oregon  97045
GSK Investigational SiteCranston, Rhode Island  02920
GSK Investigational SiteSeattle, Washington  98133